Katherine V Williams1, Dorothy J Becker2, Trevor J Orchard3, Tina Costacou4. 1. University of Pittsburgh Department of Epidemiology, DLR Building, 3512 Fifth Avenue, Pittsburgh, PA 15213, United States of America. Electronic address: kvw3@pitt.edu. 2. Children's Hospital of Pittsburgh Division of Endocrinology, 4401 Penn Avenue, Pittsburgh, PA 15224, United States of America. Electronic address: Dorothy.Becker@chp.edu. 3. University of Pittsburgh Department of Epidemiology, DLR Building, 3512 Fifth Avenue, Pittsburgh, PA 15213, United States of America. Electronic address: OrchardT@edc.pitt.edu. 4. University of Pittsburgh Department of Epidemiology, DLR Building, 3512 Fifth Avenue, Pittsburgh, PA 15213, United States of America. Electronic address: CostacouT@edc.pitt.edu.
Abstract
AIMS: The aim was to determine if persistent c-peptide in long duration childhood onset (<17 years) type 1 diabetes (T1D) related to microvascular complications. METHODS: Pittsburgh Epidemiology of Diabetes Complications (EDC) participants (n = 185) had serum c-peptide levels measured by Mercodia ultra-sensitive ELISA at the 25-year follow-up exam. Microvascular complications between those with and without detectable c-peptide were compared. RESULTS: Eighteen (9.7%) participants had detectable median c-peptide levels of 3.8 (2.6, 12.2) pmol/L and did not differ from those without detectable levels. No differences in microalbuminuria, confirmed distal symmetric polyneuropathy, renal failure, or between those with one or more complications were found between the two groups. Proliferative retinopathy (PR) was marginally lower in those with detectable c-peptide (33.3% vs 55.1%, p = 0.08). However, those with c-peptide were somewhat less likely to have fasted for a full 8-h (66.7% vs. 84.9%, p = 0.09). Excluding those not fully fasted, PR no longer approached significance but macroalbuminuria became marginally lower in those with detectable levels (23.4% vs 0%, p = 0.07). CONCLUSIONS: Low levels of c-peptide in T1D patients of long duration were detected but were not strongly related to microvascular complications.
AIMS: The aim was to determine if persistent c-peptide in long duration childhood onset (<17 years) type 1 diabetes (T1D) related to microvascular complications. METHODS: Pittsburgh Epidemiology of Diabetes Complications (EDC) participants (n = 185) had serum c-peptide levels measured by Mercodia ultra-sensitive ELISA at the 25-year follow-up exam. Microvascular complications between those with and without detectable c-peptide were compared. RESULTS: Eighteen (9.7%) participants had detectable median c-peptide levels of 3.8 (2.6, 12.2) pmol/L and did not differ from those without detectable levels. No differences in microalbuminuria, confirmed distal symmetric polyneuropathy, renal failure, or between those with one or more complications were found between the two groups. Proliferative retinopathy (PR) was marginally lower in those with detectable c-peptide (33.3% vs 55.1%, p = 0.08). However, those with c-peptide were somewhat less likely to have fasted for a full 8-h (66.7% vs. 84.9%, p = 0.09). Excluding those not fully fasted, PR no longer approached significance but macroalbuminuria became marginally lower in those with detectable levels (23.4% vs 0%, p = 0.07). CONCLUSIONS: Low levels of c-peptide in T1D patients of long duration were detected but were not strongly related to microvascular complications.
Authors: T J Orchard; J S Dorman; R E Maser; D J Becker; A L Drash; D Ellis; R E LaPorte; L H Kuller Journal: Diabetes Date: 1990-09 Impact factor: 9.461
Authors: Hillary A Keenan; Jennifer K Sun; Jared Levine; Alessandro Doria; Lloyd P Aiello; George Eisenbarth; Susan Bonner-Weir; George L King Journal: Diabetes Date: 2010-08-10 Impact factor: 9.461
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Francesco Panero; Giulia Novelli; Chiara Zucco; Paolo Fornengo; Massimo Perotto; Olivia Segre; Giorgio Grassi; Paolo Cavallo-Perin; Graziella Bruno Journal: Diabetes Care Date: 2008-11-18 Impact factor: 17.152
Authors: Rose A Gubitosi-Klug; Barbara H Braffett; Susan Hitt; Valerie Arends; Diane Uschner; Kimberly Jones; Lisa Diminick; Amy B Karger; Andrew D Paterson; Delnaz Roshandel; Santica Marcovina; John M Lachin; Michael Steffes; Jerry P Palmer Journal: J Clin Invest Date: 2021-02-01 Impact factor: 14.808